大直径覆膜支架与TEVAR术后不良结局相关:Medicare受益人群分析
本研究基于SVS-VQI与Medicare链接数据,纳入2259例TEVAR患者,比较≥40 mm与<40 mm支架的结局。大支架组30天死亡率(11% vs 8%)和并发症率(32% vs 25%)更高,1年及3年复合终点(再干预、破裂、全因死亡)显著更差,支架直径≥40 mm为独立预测因子(HR 1.3)。
要点
- TEVAR使用≥40 mm支架与30天死亡率和并发症率升高相关。
- 大支架组1年及3年主动脉相关再干预、破裂和全因死亡复合率显著更高。
- 支架直径≥40 mm是复合终点的独立预测因子(HR 1.3,95%CI 1.1-1.5)。
核心结论
- 大直径(≥40 mm)覆膜支架与TEVAR术后更差结局相关,包括30天死亡率和并发症率升高,以及1年和3年复合终点显著更差。
- 支架直径≥40 mm是主动脉相关再干预、破裂和全因死亡复合终点的独立预测因子(HR 1.3;95%CI 1.1-1.5)。
- 尽管晚期破裂事件无显著差异,但主动脉相关再干预和全因死亡率在3年时显著更差。
研究设计与样本
- 回顾性队列研究,纳入SVS-VQI(2016-2019)中所有涉及近端Ishimaru 0-7区的TEVAR手术,共2259例患者。
- 患者链接至Medicare索赔数据(VQI-VISION)以评估长期结局,按支架直径≥40 mm(681例,30%)与<40 mm分层比较。
主要发现
- 复合终点的独立预测因子包括支架直径≥40 mm(HR 1.3;95%CI 1.1-1.5)、动脉瘤直径(HR 1.0;95%CI 1.0-1.02)和年龄(HR 1.02;95%CI 1.01-1.03)。
临床怎么用
- 使用大直径(≥40 mm)覆膜支架行TEVAR时应严格评估治疗成功可能性,因其与纵向风险强烈相关。
- 器械监管机构可能需要重新评估大直径胸主动脉覆膜支架的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Multiple factors contribute to early and/or late failure after endovascular aortic repair. Notably, the impact of device-related parameters, specifically diameter, on postoperative outcomes following thoracic endovascular aortic aneurysm repair (TEVAR) has not been thoroughly explored. This study aimed to determine whether use of large diameter (≥40 mm) endografts increase the risk of adverse outcomes after TEVAR. METHODS: All TEVAR procedures involving proximal Ishimaru zones 0 to 7 in the Society for Vascular Surgery-Vascular Quality Initiative (2016-2019) were identified. Patients were linked to Medicare claims data (VQI-VISION) to assess long-term outcomes. The cohort was stratified based on endograft diameter: ≥40 mm(vs <40 mm). Preoperative characteristics, operative variables, and postoperative outcomes were compared. The primary outcome was a composite of aortic-related reintervention, rupture, and all-cause mortality. Unadjusted and adjusted Cox regression analyses were performed across outcome measures. RESULTS: A total of 2259 patients met inclusion criteria, with 681 (30%) receiving at least one ≥40 mm diameter endograft. Patients receiving large endografts (≥40 mm) were more likely to be men (n = 412; 61% vs n = 828; 53%; P = .0004), had larger preoperative aneurysm diameters (60 mm; interquartile range [IQR], 54-67 mm vs 54 mml IQR,40-61 mm; P < .0001), and had prior aortic surgery (n = 306; 45% vs n = 390; 25%; P < .0001). Patients with large endografts were more likely to have aneurysmal pathology (n = 528; 78% vs n = 935; 59%; P < .0001) as opposed to acute dissection/intramural hematoma/penetrating athersclerotic ulcer. Large endograft deployments were more likely to occur for disease extent involving the aortic arch and descending thoracic aorta (n = 463; 71% vs n = 873; 58%; P < .0001) rather than more distal thoracoabdominal disease. Procedures tended to be more complex for patients with large endografts, as evidenced by longer procedure times, increased fluoroscopy exposure, and higher contrast volume use. Patients with large endografts had significantly worse 30-day mortality (11% vs 8%; P = .02) and complication rates (32% vs 25%; P = .0006). The 1-year and 3-year composite rate of aortic-related reintervention, rupture, and all-cause mortality were significantly worse with large endografts (1-year: ≥40 mm, 37%; 95% confidence interval [CI], 33%-41% vs <40 mm, 30%; 95% CI, 28%-33%; log-rank P value = .002; 3-year: ≥40 mm, 60%; 95% CI, 55%-65% vs <40 mm, 48%; 95% CI, 44%-51%; P value < .0001). Independent predictors of the composite endpoint included endograft diameter ≥40 mm (hazard ratio [HR], 1.3; 95% CI, 1.1-1.5), aneurysm diameter (HR, 1.0; 95% CI, 1.0-1.02), and age (HR, 1.02; 95% CI, 1.01-1.03). CONCLUSIONS: Large-diameter endografts (≥40 mm) are associated with worse outcomes following TEVAR. Although there was no significant difference in late rupture events, aortic-related reintervention and all-cause mortality were significantly worse at 3 years. Treatment success should be heavily scrutinized when using large diameter endografts, as these results identify a device-specific parameter that is strongly associated with longitudinal risks. Device regulators may need to reassess the efficacy of large diameter thoracic endografts.
引用
- Arnaoutakis DJ, Nguyen T, Zheng X, et al. Large endograft diameter is associated with poor outcomes following thoracic endovascular aortic aneurysm repair in Medicare beneficiaries. J Vasc Surg. 2025. PMID: 40581193. doi:10.1016/j.jvs.2025.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。